ASP8273

· Astellas Pharma Global Development, Inc.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for ASP8273, covering 2017-07-11 to 2024-11-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]

See pricing